Because the TLR1/TLR2 agonist Pam3CSK4 was shown to inhibit MLL‐AF9‐driven leukemogenesis (Eriksson et al, 2017), we next assessed the combined therapeutic effect of MPA and Pam3CSK4 on human MLL‐AF9‐expressing CB cells and the in vivo mouse AML model driven by MLL‐AF9. The gene discussed is KMT2A; the disease is acute myeloid leukemia.